Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-label, Phase II, Single Arm Study to Evaluate the Safety, Immunogenicity, Pharmacokinetics and Efficacy of rhC1INH for the Treatment of Acute Attacks in Pediatric Patients With Hereditary Angioedema, From 2-13 Years of Age

Next Previous
Trial Profile

Open-label, Phase II, Single Arm Study to Evaluate the Safety, Immunogenicity, Pharmacokinetics and Efficacy of rhC1INH for the Treatment of Acute Attacks in Pediatric Patients With Hereditary Angioedema, From 2-13 Years of Age

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 01 Apr 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Conestat alfa (Primary)
  • Indications Hereditary angioedema
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Sponsors Pharming Group NV

Most Recent Events

  • 29 Apr 2020 According to a Pharming Group media release, European Commission has approved an extension in the indication of RUCONEST (conestat alfa) Marketing Authorisation to include the treatment of acute angioedema attacks in children with hereditary angioedema (HAE). This marketing authorisation expands the age range of Pharming lead product, RUCONEST.The European Commission decision allows children aged two years and older to be treated with RUCONEST for acute angioedema attacks.
  • 27 Mar 2020 According to a Pharming Group media release, the positive opinion is based on the data from this Phase II clinical trial in 20 children.This recommendation will allow children aged 2 years and older to be treated with RUCONEST for acute angioedema attacks. The European Commissions (EC) approval decision is expected in June 2020.
  • 27 Mar 2020 According to a Pharming Group media release, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicine Agency (EMA) has recommended approval of RUCONEST (conestat alfa) for the treatment of acute angioedema attacks in children with hereditary angioedema (HAE). This marketing authorisation would expand the age range of RUCONEST which was previously approved for adults (since 2010) and adolescents (since 2016) in Europe.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top